Introduction
============

Albumins and globulin are the main components of serum proteins. Albumins reflect the nutrition status of the human body, which are functioning as the regulators of colloid osmotic pressure of blood. Moreover, they also bind cations, fatty acids, bilirubin, hormones and pharmaceuticals and act like the transporters. Besides, it also involves in various sorts of physiological activities of human bodies. Lower albumin levels indicated poor nutrition status which had been reported to predict poor survival in various type of cancers in the previous studies[@B1]-[@B5]. Globulin family has several members including alpha, beta, and gamma globulins. Among them, gamma globulin accounts for the largest proportion. It is known as immunoglobulin or antibody and secreted by B cells of the adaptive immune system. Therefore, it plays an important role in immunity. An increased level of globulin has been proved to be related to chronic inflammation[@B6]-[@B8]. Chronic inflammation increases the acute phase proteins in human bodies (eg: C-reactive protein, serum amyloid, complement C3, fibrinogen, ceruloplasmin et.al.). They are all parts of globulins which are markers of chronic inflammation when they are elevated in various levels. It reflects the accumulation of various proinflammatory cytokines, such as interleukin(IL, especially IL-6 and IL-1β) and tumor necrosis factor[@B9]-[@B10]. Besides chronic inflammation, globulin has been reported to be increased in various types of cancer especially in hematologic cancers. In multiple myeloma, lymphoma and light chain disease, some particular globulins would significantly increase and could be detected not only in the serum, but also in the urine or other body fluid [@B11]-[@B13].

As closely associated with the nutrition status and immune system activity, albumin and globulin had remarkable value in the prognosis of cancers. Albumin-to-globulin ratio (AGR) which was calculated from the equation of albumin/(total proteins - albumin), had been suggested and considered as an effective combination of two strong prognostic factors. In the hematologic tumor, it had been reported that lower AGR predicted poorer survival outcomes in lymphoma[@B14].

In terms of non-hematologic solid tumors, numbers of researches have been performed to study the prognostic value of AGR[@B15]-[@B36]. However, there is still no consensus on the prognostic effect of AGR in solid tumors. Besides, the cut-off values in studies were undetermined. Therefore, we performed a systemic review and meta-analysis to elucidate the prognostic value of AGR on clinical outcomes in solid tumor patients. Moreover, we intend to verify its prognostic effect in different cut-off intervals.

Materials and Methods
=====================

Data source
-----------

The electronic search was performed using PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trial, Cochrane Database of Systematic Reviews, ACP Journal Club and Database of Abstracts of Reviews of Effects and PMC database from the date of the earliest publication (1962) to April 2017. This study was conducted in accordance with evidence-based minimum set of items for reporting in systematic reviews and meta-analyses (PRISMA).

Search strategy
---------------

In order to achieve the maximum sensitivity, we used the following search strategy: (\"albumins\"\[MeSH Terms\] OR \"albumins\"\[All Fields\] OR \"albumin\"\[All Fields\]) AND (\"globulins\"\[MeSH Terms\] OR \"globulins\"\[All Fields\] OR \"globulin\"\[All Fields\]) AND (\"ratio\"\[All Fields\]) AND (\"neoplasms\"\[MeSH Terms\] OR \"neoplasms\"\[All Fields\] OR \"cancer\"\[All Fields\]). All the articles were filtered by inclusion and exclusion criteria. When duplicated data was encountered, only the latest and complete reports were included for data extraction and assessment.

Inclusion and exclusion criteria
--------------------------------

The selection criteria were as follow: (1) patients with non-hematologic solid tumors; (2) prognostic effect of AGR was evaluated on overall survival (OS), disease-free survival (DFS) and/or recurrent-free survival (RFS), disease-metastasis-free survival (DMFS), and cancer-specific survival (CSS); (3) the studies were reported in terms of hazard ratio (HR) and its 95% confidence interval (CI) or the Kaplan-Meier Curve which the HR was calculated from or the p values and cohort numbers from the outcomes with Parmar\'s method[@B32]; (4) the cut-off value of AGR which had been reported. The candidate articles would be excluded if they met the following exclusion criteria: (1) patients with hematologic cancers; (2) case reports, abstracts, expert opinion, conference presentation, guidelines and reviews; (3) less than 20 patients in either arm; (4) insufficient data for estimating the HR, 95%CI or p value; (5) no cut-off value of AGR reported or only reported as a continuous variable; (6) non-English publications; (7) non-human research.

Data extraction
---------------

All the data were independently extracted from the articles, tables, figures and supplement of the publications by three inspectors (DK. X, XW. C and MZ. G). Discrepancies between reviewers were resolved by the discussion and consensus with the senior investigators (JX. H, H. P and WH. L). The publication characteristics and time-to-event data were extracted and recorded as: first author, publication year, study type, cancer site, study duration, institute, disease stage (non-metastatic, metastatic or mixed), number of patients, group number, average age, mean or median age, gender, follow-up duration, albumin and globulin level, mortality, cut-off value, HR of each clinical outcomes (OS, CSS, DFS/RFS, and DMFS), 95%CI and p value (Figure [1](#F1){ref-type="fig"}). HRs would be extracted or calculated from the Kaplan-Meier Curves if they were not directly provided in the articles.

Statistical analysis
--------------------

A systemic review and meta-analysis was performed to illustrate the prognostic value of AGR and OS of patients with solid tumors. The secondary outcomes were DFS/RFS, CSS and DMFS. HRs and 95% CIs of the outcomes were extracted from the articles. When the data were not reported in the articles, HRs and their 95% CIs would be calculated from the provided data or specific points in the Kaplan-Meier Curves using the methods from Parmar et. al[@B32]. In order to minimize this interference induced by the number of studies, I² test was used to estimate the variation across the studies instead of the Q test, because Q test results were closely related to the number of included studies. The I² was calculated by the formula: ![](jcav08p4002i001.jpg); Q stood for a heterogeneity statistic and df was defined as the degree of freedom (df=total number of trials - 1). The heterogeneity was defined as low (25%-49%), moderate (50%-74%) or severe (\>75%). Fixed-effect analysis model was used to calculate the HR. Heterogeneity would be considered as significant if the p values less than 0.1. If it was severe, a random-effect analysis model would be used. In addition, the sensitivity test or subgroup analysis would be performed. In terms of specific categories, subgroup analyses were conducted according to cancer types, disease stages and AGR cut-off value. Z-test was performed to calculate the p value, which was two-sided and defined as statistically different when p\<0.05. No publication bias was observed via Begg test and Egger test in the analysis. The statistical analysis was conducted via the comprehensive meta-analysis program (Version 3, Biostat, Englewood, NJ USA).

Results
=======

Selection process and cohort characteristics
--------------------------------------------

A search of electronic databases revealed a total of 491 potential articles for analysis. Among them, 25 articles were excluded as duplicate data. A number of 466 full-text articles were selected for further investigation, while no extra article was included from other source. After apply the exclusion criteria, 445 articles had to be excluded from the analysis. Finally, a total of 21 studies were chosen for data extraction and meta-analysis[@B15]-[@B36]. The selection process and the reasons for exclusion were demonstrated in the diagram (Figure [1](#F1){ref-type="fig"}). All studies were retrospective. Among them, cancers from digestive system accounted for the largest proportion (11/24) including colorectal cancer, gastric cancer, esophageal cancer and hepatocellular cancer. Referring to the disease stage, 18 studies were 21 studies determined AGR cut-off values via ROC sensitivity and specificity analysis (Youden index or Concordance Index), while 3 studies determined their cut-off values by tertiles and one study provided no information about the method of deciding AGR cut-off value. The characteristics of studies were shown in Table [1](#T1){ref-type="table"}.

Overall survival
----------------

A number of 13890 patients were included from 24 articles for the analysis of overall survival (OS). Compared to lower AGR patients, higher AGR patients had better overall survival (HR=0.580, 95%CI 0.537-0.626, p\<0.001, Figure [2](#F2){ref-type="fig"}). Due to the heterogeneity, the random-effect model was utilized (I^2^=67.4%, p\<0.001). In the subgroup analysis, it showed that higher AGR was associated with an ideal overall survival in each type of malignancies (Table [2](#T2){ref-type="table"}). The cut-off values from studies varied from 0.7 to 1.75. Therefore, we separated the included studies into 3 categories according to the tertile interval of the cut-off values. There were 6 studies in ≤1.20 group, 9 studies in \>1.20 to \<1.40 group and 6 studies in ≥1.40 group. We observed the same results in three subgroups that higher AGR predicted better overall survival (Group1: HR=0.371, 95%CI 0.235-0.586, p\<0.001; Group2: HR=0.573, 95%CI 0.489-0.671, p\<0.001; Group3: HR=0.617, 95%CI 0.550-0.692, p\<0.001). In terms of disease stage, high AGR was related to better prognosis in metastatic disease (HR=0.49, 95%CI 0.28-0.87, p\<0.001), in non-metastatic disease (HR=0.61, 95%CI 0.54-0.72, p\<0.001) and in mixed group including metastatic and non-metastatic diseases (HR=0.57, 95%CI 0.516-0.625, p\<0.001).

Disease-free survival or Recurrence-free survival
-------------------------------------------------

A total of 6541 patients in 6 studies were available for disease-free survival (DFS) or recurrence-free survival (RFS) data extraction[@B25]-[@B27], [@B30], [@B33], [@B35]. Patients whose AGRs were higher than cut-off value had better clinical outcomes (HR=0.792, 95%CI 0.715-0.878, p\<0.001; Figure [3](#F3){ref-type="fig"}). The random-effect model was utilized due to the significant heterogeneity (I^2^=67.1%, p=0.01).

Distant metastasis-free survival and Cancer-specific survival
-------------------------------------------------------------

Only 2 studies including 1214 patients had reported the distant metastasis-free survival (DMFS) data[@B17], [@B19]. The result of analysis showed that high AGR was associated with ideal DMFS (HR=0.595, 95%CI 0.447-0.792, p\<0.001). The fixed-effect model was selected while the heterogeneity was insignificant (I^2^=8.73, p=0.295) (Figure [4](#F4){ref-type="fig"}).

Cancer-specific survival
------------------------

A total of 3 studies comprising 899 patients reported the cancer-specific survival (CSS)[@B22], [@B24], [@B27]. Better prognostic outcomes were observed in higher AGR patients in terms of CSS (HR=0.287, 95%CI 0.187-0.438, p\<0.001). According to the significant heterogeneity, the random-effect model was used in CSS analysis (I^2^=73.65, p=0.022).

Discussion
==========

Albumin accounts for the largest proportion of serum protein which plays a crucial role of human body. A normal level of albumin (\>3.5g/dl) is indispensable in the physiological activities of human body. It is generated by liver and acting as one of the biomarkers for liver function evaluation (Child-Pugh)[@B38]. Low albumin was not only associated to the poor nutrition status, but also a negative predictor for clinical outcomes of various malignancies[@B39]-[@B41]. Referring to the non-albumin proteins, they are also named as calculated globulins which are calculated by the formula (Total serum proteins-albumin). The calculated globulins contain a large amount of immunity-related proteins such as immunoglobulins, complements, C-reaction proteins (CRP), interleukins, TNF, et.al. Some researchers reported that tumor biomarkers including CA 19-9 and CEA were also considered as calculated globulins[@B15]. Previous studies had showed the predictive value of such inflammatory proteins. High level of compliment 3 (C3) and IgA indicated poor prognosis in colorectal cancer patients. Moreover, C3 and C4 had been reported to be the negative prognostic factors in NSCLC[@B42], [@B43]. Higher CRP level was associated with decreased survival in gastrointestinal cancer and lung cancer patients[@B5], [@B44], [@B45].

The mechanisms of correlation of AGR and solid tumor survival have not been fully understood. In the previous studies, poor nutrition status (hypoalbuminemia) had been proved to be a negative prognostic factor of long-term survival in many tumors including gastrointestinal, lung, hepatobiliary, CNS, reproductive and breast cancers[@B15], [@B46], [@B47]. Additionally, normal albumin level was reported to be crucial for the drug delivery in chemotherapy[@B48], [@B49]. On the other hand, chronic inflammatory is considered as a contributor for tumor proliferation, immune evasion, and metastasis involving all kinds of serum globulins (CRP, TNF, immunoglobulins, and other cytokines). These serum globulins secreted by tumor-related cells were reported to promote tumor development, angiogenesis, immunosuppression, and metastasis. Therefore, low albumins and high globulins which indicated poor nutrition status and the extent of severe chronic inflammation could decrease the survival of cancer patients.

Chronic inflammation is associated with the occurrence, proliferation, survival, metastasis and the recurrence of cancer [@B50], The occurrence of tumors involves the interaction between the immune system, interstitial cells and malignant cells. Inflammatory factors promote cell proliferation and induce tumor suppressor gene mutation or cell cacinogenesis by altering the cell microenvironment. The presence of inflammation is conducive to the occurrence of cancer. On the other hand, the tumor has exacerbated the inflammatory response. Chronic inflammation regulates T cells, Th2 cells and activated B cells accumulate. The polarization effect of multiple cytokines on tumor related macrophages is mediated. Ultimately, it leads to the development and progression of cancer[@B51]. Tumor-associated macrophages and inflammatory cytokines promote tumor growth, progression, angiogenesis metastasis and immunosuppression [@B51]-[@B54].

Instead of albumins and globulins absolute levels, AGR was a ratio which was a combination of two independent prognostic factors. Since the albumins and globulins were conversely correlated to the solid tumor survival, AGR was more significant and precise to demonstrate the prognostic effect. Firstly, it greatly decreased the possible influence from the variation of albumins or globulins which might be generated by measurement error or abnormal situations including fluid retention and dehydration. Besides, both variations from albumins and globulins would result in AGR changes synchronously. Therefore, we believed AGR was capable for outcomes evaluation.

Dias et.al firstly reported that AGR was lower in retinoblastoma patients comparing to the control[@B55]. Further, Cohen et.al reported that both low albumins and high immunoglobulins had negative effect in small cell lung cancer prognosis[@B43]. However, few studies had reported the prognostic value of AGR in solid tumors. Until recently, numbers of researches had studies the correlation between AGR and the survival outcomes of solid tumor. Considering the absence of consensus on AGR and outcomes of solid tumor, we therefore performed this analysis. The results showed that high AGR was associated with favorable OS, DFS, DMFS and CSS. Besides, the results of subgroup analysis including disease stage, tumor types, and different cut-off value, demonstrated an ideal concordance that higher AGR had a positive effect to the overall survival of patients with solid tumors.

Limitations should be admitted in this study. First, the original data from the included studies were not available. As a result, the analysis had to be performed via extracted data from the articles. Additionally, the included articles were retrospective studies. A large proportion of them provided HRs, 95%CI and p values from the univariate analysis. However, these data were not available in some studies that we had to estimate HR and 95%CI from Kaplan-Meier curve. It could lead to overestimation of the prognostic effect. Second, a moderate heterogeneity was observed between studies in OS analysis. Therefore, the random-effect model was selected. The sensitivity test was performed to identify the study contributing most to the heterogeneity. The result was not influenced by the deletion of the study. Third, the cut-off values from the included studies were inconsistent since they had been verified from different tumors or even different methods. Among them, the cut-off values from 3 studies were identified as the tertile interval. Therefore, it was unable to verify in this study.

In summary, our study indicates that high AGR has significant positive prognostic effect on the survival in different solid tumor patients including both non-metastatic and metastatic patients. AGR is useful and available in the clinical practice. Further investigation and research are warranted to verify its role in the diagnosis and evaluation of the solid tumor. Moreover, the specific cut-off value of AGR in each type of cancer should be identify and validated.
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###### 

The characteristics of the included studies

  Author              Year   Cancer Type                          Duration    Region   Disease stage    No.    Age(Median)     Follow-up(Median)   Cut-off
  ------------------- ------ ------------------------------------ ----------- -------- ---------------- ------ --------------- ------------------- ---------------------------------------------
  Azab (Ⅰ)            2013   Colorectal Cancer                    2005-2011   USA      Mixed            534    69\*            40                  \<1.028, \[1.028-1.321\], \>1.321 (tertile)
  Azab (Ⅱ)            2013   Breast Cancer                        2004-2006   USA      Mixed            354    63.7\*          48                  \<1.21, \[1.21-1.45\], \>1.45 (tertile)
  Duran               2014   Lung Adenocarcinoma                  2007-2011   Turkey   Mixed            240    58.7\*          NA                  0.7,1.0,1.4(average)
  Du                  2014   Nasopharyngeal Carcinoma             2003-2006   China    Mixed            694    44(13-78)       88(5-123)           \<1.4
  Chen                2015   Gastric Cancer                       2007-2010   China    Mixed            186    61(19-82)       NA                  ≤1.33
  Li                  2015   Nasopharyngeal Carcinoma             2001-2009   China    Mixed            520    43(13-78)       88.4(4.2-150.6)     ≤1.34
  Shibutani           2015   Metastatic Colorectal Cancer         2006-2011   Japan    Metastatic       66     63(36-80)       NA                  ≤1.25
  Zhang               2015   Upper Tract Urothelial Carcinoma     2006-2008   China    Mixed            187    70(61-74)※      78(32-92)※          \<1.45
  Qingguo Li          2015   Rectal Cancer                        2006-2012   China    Mixed            293    NA              NA                  ≤1.2
  Deng                2016   Hepatocellular Carcinoma             2002-2012   China    Non-metastatic   172    53(24-80)       NA                  \<1.48
  Liu                 2016   Bladder Urothelial Carcinoma         2000-2013   China    Non-metastatic   296    61.7(33-89)     72(49-121)※         \<1.60
  Toiyama             2016   Gastric Cancer                       2001-2011   Japan    Mixed            384    67(32-88)       47.6                ≤1.38
  Yaqi Li             2016   Colorectal Cancer                    2007-2014   China    Non-metastatic   5336   59(51-66)※      55.2                \<1.5
  Zhang               2016   Hepatocellular Carcinoma             2008-2012   China    Mixed            105    49(24-72)       NA                  \<1.18
  Zhou(training)      2016   Small Cell Lung Cancer               2003-2009   China    Mixed            276    59(52-66)※      NA                  \<1.29
  Zhou (validation)   2016   Small Cell Lung Cancer               2008-2011   China    Mixed            379    60(54-66)※      NA                  \<1.29
  Fei Zhang,          2016   Esophageal Squamous Cell Carcinoma   2006-2010   China    Mixed            458    59(20-88)       NA                  \<1.30
  Asude Aksoy         2016   Gastric Carcinoma                    2009-2014   Turkey   Metastatic       204    59\*            66.39\*             1.14
  Chen                2016   Clear Cell Renal Cell Carcinoma      2003-2013   China    Mixed            416    56.3(24-80)     69.2(1-151)         ≤1.22
  He                  2017   Renal Cell Carcinoma                 2000-2012   China    Mixed            895    51.44±13.44\*   69.68               ≤1.47
  Xu                  2017   Glioblastoma                         2010-2015   China    Non-metastatic   166    50.41±14.5\*    14(1-52)            ≤1.75
  Hiroyuki Fujikawa   2017   Colon Cancer                         2002-2012   Japan    Non-metastatic   248    70(27-88)       49.7(46.8-57.0)     \<1.32
  Mao(Testing)        2017   Gastric Cancer                       2009-2013   China    Mixed            431    59(26-85)       NA                  ≤1.5
  Mao(Validate)       2017   Gastric Cancer                       2009-2013   China    Mixed            431    59(26-85)       NA                  ≤1.5
  Oki                 2017   Esophageal Cancer                    2002-2014   Japan    Mixed            112    68(41-90)       24.9(27.6-36.2)     ≤1.41
  Liu                 2017   Gastric Cancer                       2005-2012   China    Non-metastatic   507    58.8            NA                  \<1.93

###### 

The hazard ratio for overall survival in different subgroups: tumor type, disease stage and cut-off value

                                       No.   HR      95%CI         P value
  ------------------------------------ ----- ------- ------------- ---------
  **Tumor type**                                                   
  Colorectal cancer                    5     0.505   0.399-0.640   \<0.001
  Breast cancer                        1     0.242   0.139-0.422   \<0.001
  Lung Adenocarcinoma                  1     0.687   0.535-0.883   0.003
  Nasopharyngeal Carcinoma             2     0.695   0.502-0.963   0.029
  Gastric cancer                       5     0.609   0.504-0.738   \<0.001
  Upper tract urothelial carcinoma     2     0.452   0.271-0.751   0.002
  Hepatocellular carcinoma             2     0.296   0.195-0.448   \<0.001
  Small cell lung cancer               1     0.721   0.582-0.893   0.003
  Esophageal Squamous cell carcinoma   1     0.759   0.507-1.137   0.181
  Esophageal Carcinoma(Mixed)          1     0.47    0.240-0.920   0.028
  Clear cell renal cell carcinoma      2     0.473   0.335-0.668   \<0.001
  Glioblastoma                         1     0.785   0.357-0.979   0.04
  **Disease stage**                                                
  non-metastatic                       5     0.61    0.54-0.72     \<0.001
  metastatic                           2     0.49    0.28-0.87     \<0.001
  mixed                                17    0.57    0.52-0.62     \<0.001
  **Cut-off value**                                                
  ≤1.20                                6     0.371   0.235-0.586   \<0.001
  \>1.20 to \<1.40                     9     0.573   0.489-0.671   \<0.001
  ≥1.40                                9     0.617   0.550-0.692   \<0.001
  **Overall**                          24    0.578   0.533-0.626   \<0.001
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